STORY / PUBLIC SOURCE RECORD
Norway’s health companies step up despite global market uncertainty
- Published 4 June 2025; updated 25 March 2026; estimated reading time 2 minutes. The article reports on a May 2025 Oslo “Landslagstreff #2” under the national health and life-science export initiative. It says 67% of Norwegian health exports went to Europe and the US and reiterates the initiative’s goal to double non-oil-and-gas health exports by 2030. These are article-reported figures/targets.
- Embassy representatives from Washington and Berlin, Innovation Norway, the Confederation of Norwegian Enterprise, the Ministry of Trade, Industry and Fisheries and the Ministry of Foreign Affairs discussed support for companies abroad. Industry leaders from Laerdal Medical, Bayer and Curida Diatec discussed scaling via partnerships, regulatory knowledge and international positioning.
- Initiative actions listed: a Berlin delegation under the German–Norwegian health agreement; a radiopharma trade mission to Japan ahead of Expo 2025; strategic US-market follow-up; and a nationwide baseline study mapping health-export opportunities/barriers. A group of 37 export-ready companies (“the national team”) had been assembled, with further firms to join through Innovation Norway’s international network.
- The article describes opportunities in European markets and the US and highlights radiopharmaceuticals, AI monitoring, infection prevention and remote-care platforms. Contact: Tone Varslot Stave, head of the national export initiative at Innovation Norway, tone.varslot.stave@innovasjonnorge.no (phone number available through an on-page reveal control). Related industry: Health and life science.